

Data Sharing Statement

Vogelzang. Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer. *JAMA Oncol.* Published February 10, 2022.
doi:10.1001/jamaoncol.2021.7298

Data

Data available: No

Additional Information

Explanation for why data not available: The datasets generated during and/or analyzed during the current trial are not publicly available due to commercial requirements, but are available from the corresponding author on reasonable request (Dr Nicholas Vogelzang, email: Nicholas.vogelzang@usoncology.com)